STUDY THE SERUM LEVELS OF IL-17, IL-23, TLR-4, TLR-7 ROLE IN IMMUNOPATHOGENESIS IN PATIENTS WITH PSORIASIS
Keywords:
Interleukin-17, Interleukin-23, Toll-like receptors-4, Toll-like receptors-7, PsorisisAbstract
Objective: The purpose of this study is to examine the relationship between immunological markers (IL-17, IL-23, TLR4, and TLR-7) and several socio-demographic parameters, including age, sex, disease severity, stress, smoking behaviors, BMI classification, and dietary preferences, in patients with psoriasis.
Methods: This study investigates the incidence of psoriasis among patients at Imam Al-Hussein City Hospital in Karbala, Iraq, during the period spanning from December 2022 to April 2023. The study encompassed a heterogeneous sample of individuals, comprising both individuals in optimal health and those who had recently received a diagnosis but had not yet commenced therapy. The research employed a case-control design with convenience sample and evaluated four anatomical regions using the Psoriasis Area and Severity Index (PASI) scoring system. The sandwich enzyme-linked immunosorbent assay (ELISA) technique was employed to conduct an inquiry on immunomarkers.
Results: The analysis reveals a higher prevalence of psoriasis patients (50%) compared to the control group (40%), with no significant differences in age or gender. The female population had a numerical superiority, accounting for 56% of the total, while the male population had 35%. There was a significant difference in body mass index (BMI) values between healthy controls and psoriasis patients, but statistically distinguishable differences. Smoking prevalence was significantly higher in psoriasis patients compared to the general population. Both groups exhibited adherence to a nutritionally balanced diet, with most patients presenting moderate intensity symptoms. Immunological markers, including IL-17, IL23, TLR-4, and TLR-7, were found to be elevated in psoriasis patients compared to healthy individuals, suggesting a potential association between these markers and the disease's aetiology.
Conclusion: Psoriasis patients make up a significant part of the study population, with higher smoking, stress, and healthy food habits. There's no significant difference in BMI, disease severity, or immunological markers.
References
Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Vol. 445, Nature. 2007.
Rendon A, Schäkel K. Psoriasis pathogenesis and treatment. Vol. 20, International Journal of Molecular Sciences. 2019.
Kanda N. Psoriasis: Pathogenesis, comorbidities, and therapy updated. Vol. 22, International Journal of Molecular Sciences. 2021.
Hart PH, Gorman S, Finlay-Jones JJ. Modulation of the immune system by UV radiation: More than just the effects of vitamin D? Vol. 11, Nature Reviews Immunology. 2011.
Bauer E, Lucier J, Furst DE. Brodalumab-An IL-17RA monoclonal antibody for psoriasis and psoriatic arthritis. Expert Opin Biol Ther. 2015;15(6).
Nwe SM, Champlain AH, Gordon KB. Rationale and early clinical data on IL-17 blockade in psoriasis. Vol. 9, Expert Review of Clinical Immunology. 2013.
Gottlieb AB, Chaudhari U, Baker DG, Perate M, Dooley LT. The National Psoriasis Foundation Psoriasis Score (NPF-PS) system versus the Psoriasis Area Severity Index (PASI) and Physician’s Global Assessment (PGA): a comparison. J Drugs Dermatol. 2003;2(3).
Leonardi C, Matheson R, Zachariae C, Cameron G, Li L, Edson-Heredia E, et al. Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis. New England Journal of Medicine. 2012;366(13).
Hassoon HJ, Risan FA, Abdul-Muhaimen N. Estimation the concentration of IL-23, and IL-17A in the sera of patients with psoriasis in Baghdad city. Iraqi Journal of Biotechnology. 2014;13(2).
Arakawa A, Siewert K, Stöhr J, Besgen P, Kim SM, Rühl G, et al. Melanocyte antigen triggers autoimmunity in human psoriasis. Journal of Experimental Medicine. 2015;212(13).
Ben Abdallah H, Johansen C, Iversen L. Key Signaling Pathways in Psoriasis: Recent Insights from Antipsoriatic Therapeutics. Psoriasis: Targets and Therapy. 2021;Volume 11.
Morizane S, Gallo RL. Antimicrobial peptides in the pathogenesis of psoriasis. Journal of Dermatology. 2012;39(3).
Hawkes JE, Yan BY, Chan TC, Krueger JG. Discovery of the IL-23/IL-17 Signaling Pathway and the Treatment of Psoriasis. The Journal of Immunology. 2018;201(6).
Nie L, Cai SY, Shao JZ, Chen J. Toll-Like Receptors, Associated Biological Roles, and Signaling Networks in Non-Mammals. Vol. 9, Frontiers in Immunology. 2018.
Duan T, Du Y, Xing C, Wang HY, Wang RF. Toll-Like Receptor Signaling and Its Role in Cell-Mediated Immunity. Vol. 13, Frontiers in Immunology. 2022.
Moore DS, McCabe GP, Craig BA, McCabe GP, Craig BA. Introduction to the Practice of Statistics. 9th Ed. Macmillan Learning. Macmillan Learning; 2021. 20–35 p.
Parisi R, Symmons DPM, Griffiths CEM, Ashcroft DM. Global epidemiology of psoriasis: A systematic review of incidence and prevalence. Journal of Investigative Dermatology. 2013;133(2).
Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007 Jul;370(9583):263–71.
Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol. 2006;55(5).
Kampe T, Dorko E, Rimárová K, Houžvičková A, Baloghová J, Baranová Z, et al. PREVALENCE OF CARDIOVASCULAR RISK FACTORS IN PATIENTS WITH PSORIASIS. Cent Eur J Public Health. 2022;30.
Thomas L, Canoui-Poitrine F, Gottenberg JE, Economu-Dubosc A, Medkour F, Chevalier X, et al. Incidence of new-onset and flare of preexisting psoriasis during rituximab therapy for rheumatoid arthritis: Data from the French AIR registry. Vol. 39, Journal of Rheumatology. 2012.
Kawada JI, Kimura H, Ito Y, Hara S, Iriyama M, Yoshikawa T, et al. Systemic cytokine responses in patients with influenza-associated encephalopathy. Journal of Infectious Diseases. 2003;188(5).
Langley RGB, Krueger GG, Griffiths CEM. Psoriasis: Epidemiology, clinical features, and quality of life. In: Annals of the Rheumatic Diseases. 2005.
Duarte GV, Faillace C, Freire De Carvalho J. Psoriatic arthritis. Vol. 26, Best Practice and Research: Clinical Rheumatology. 2012.
Dogra S, Yadav S. Psoriasis in India: Prevalence and pattern. Vol. 76, Indian Journal of Dermatology, Venereology and Leprology. 2010.
Guillet C, Seeli C, Nina M, Maul LV, Maul JT. The impact of gender and sex in psoriasis: What to be aware of when treating women with psoriasis. Int J Womens Dermatol. 2022;8(2).
Sobhan M, Farshchian M. Associations between body mass index and severity of psoriasis. Clin Cosmet Investig Dermatol. 2017;10.
Zhou H, Wu R, Kong Y, Zhao M, Su Y. Impact of smoking on psoriasis risk and treatment efficacy: a metaanalysis. Journal of International Medical Research. 2020;48(10).
Alwan W, Nestle FO. Pathogenesis and treatment of psoriasis: Exploiting pathophysiological pathways for precision medicine. Clin Exp Rheumatol. 2015;33.
Ayasse MT, Buddenkotte J, Alam M, Steinhoff M. Role of neuroimmune circuits and pruritus in psoriasis. Vol. 29, Experimental Dermatology. 2020.
Woźniak E, Owczarczyk-Saczonek A, Placek W. Psychological stress, mast cells, and psoriasis—is there any relationship? Int J Mol Sci. 2021;22(24).
van Acht MR, van den Reek JM, de Jong EM, Seyger MM. The Effect of Lifestyle Changes on Disease Severity and Quality of Life in Patients with Plaque Psoriasis: A Narrative Review. Psoriasis: Targets and Therapy. 2022;Volume 12.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing
Ninety Nine Publication publishes articles under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This licensing allows for any use of the work, provided the original author(s) and source are credited, thereby facilitating the free exchange and use of research for the advancement of knowledge.
Detailed Licensing Terms
Attribution (BY): Users must give appropriate credit, provide a link to the license, and indicate if changes were made. Users may do so in any reasonable manner, but not in any way that suggests the licensor endorses them or their use.
No Additional Restrictions: Users may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
